Aseptic loosening of an implant after total joint arthroplasty is still a major complication that results from periprosthetic osteolysis. Fibroblasts in the interface membrane express receptor activator of nuclear factor kappa B ligand (RANKL) and stimulate osteoclast formation. Studies demonstrate that through the control of osteoclastic bone loss bisphosphonates inhibit wear particle-induced bone resorption around total hip arthroplasty. The majority of bisphosphonates studies have focused on their effects on osteoblasts and osteoclasts. Little attention has been paid to their action on fibroblasts.
Methods
We isolated fibroblasts from the interface membrane that was obtained when revision hip arthroplasty was performed because of aseptic loosening. Fibroblasts were stimulated with alendronate. RANKL and osteoprotegerin (OPG) assays were performed using enzyme-linked immunosorbent assay kit and real time Reverse Transcription- Polymerase Chain Reaction (RT-PCR).
Results
We found that alendronate stimulated OPG mRNA and protein expression in a time and dose dependent manner. By contrast, alendronate did not affect RANKL expression.
Conclusions
The results indicate that alendronate modulated OPG production by fibroblasts from periprosthetic membrane, which may prove helpful for the inhibition of bone loss during aseptic loosening following total joint arthroplasty.
CrottiTNSmithMDFindlayDMFactors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin.Biomaterials2004;25(4):565–573
2.
MandelinJLiljeströmMLiTFPseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation.J Biomed Mater Res B Appl Biomater2005;74(1):582–588
3.
MandelinJLiTFLiljeströmMImbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement.J Bone Joint Surg Br2003;85(8):1196–1201
4.
SakaiHJingushiSShutoTFibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells.Ann Rheum Dis2002;61(2):103–109
5.
MandelinJLiTFHukkanenMInterface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.J Rheumatol2005;32(4):713–720
6.
KorenyTTunyogi-CsapóMGálIVermesCJacobsJJGlantTTThe role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis.Arthritis Rheum2006;54(10):3221–3232
7.
WeiXZhangXZuscikMJDrissiMHSchwarzEMO'KeefeRJFibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles.J Bone Miner Res2005;20(7):1136–1148
8.
SunSGMaBAZhouYZhangMHFanQYEffects of bone cement particles on the function of pseudocapsule-derived fibroblasts.Acta Orthop2006;77(2):320–328
9.
ChildsLMPaschalisEPXingLIn vivo RANK signaling blockade using the receptor activator of NF-kappaB: Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.J Bone Miner Res2002;17(2):192–199
10.
RodanGAMartinTJTherapeutic approaches to bone diseases.Science2000;289(5484):1508–1514
11.
BoneHGHoskingDDevogelaerJPAlendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med2004;350(12):1189–1199
12.
WalshJPWardLCStewartGOA randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.Bone2004;34(4):747–754
13.
WellingtonKGoaKLZoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.Drugs2003;63(4):417–437
14.
LaneJMKhanSNO'ConnorWJBisphosphonate therapy in fibrous dysplasia.Clin Orthop Relat Res2001;(382):6–12
15.
DevogelaerJPNew uses of bisphosphonates: osteogenesis imperfecta.Curr Opin Pharmacol2002;2(6):748–753
16.
LehmannHJMouritzenUChristgauSCloosPAChristiansenCEffect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.Ann Rheum Dis2002;61(6):530–533
17.
MaksymowychWPBisphosphonates for arthritis—a confusing rationale.J Rheumatol2003;30(3):430–434
18.
TsutsumiRHockCBechtoldCDDifferential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.J Orthop Res2008;26(10):1340–1346
19.
ShanbhagASHasselmanCTRubashHEThe John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model.Clin Orthop Relat Res1997;(344):33–43
20.
VenesmaaPKKrögerHPMiettinenHJJurvelinJSSuomalainenOTAlhavEMAlendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study.J Bone Miner Res2001;16(11):2126–2131
21.
SoininvaaraTAJurvelinJSMiettinenHJSuomalainenOTAlhavaEMKrögerPJEffect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients.Calcif Tissue Int2002;71(6):472–477
22.
WangCJWangJWWengLHHsuCCHuangCCChenHSThe effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty.J Bone Joint Surg Am2003;85(11):2121–2126
23.
AstrandJAspenbergPReduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.Acta Orthop Scand2002;73(1):24–30
24.
TrevisanCNavaVMattavelliMParraCGBisphosphonate treatment for osteolysis in total hip arthroplasty. A report of four cases.Clin Cases Miner Bone Metab2013;10(1):61–64
25.
IolasconGDi PietroGCapaldoAGioiaCGattoSGimiglianoFPeriprosthetic bone density as outcome of therapeutic response.Clin Cases Miner Bone Metab2010;7(1):27–31
26.
QianYZhangXLZengBFJiangYShenHWangQSubstance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane.Connect Tissue Res2013;54(6):361–366
27.
QianYZengBFZhangXLJiangYSubstance P stimulates production of interleukin 1beta and tumor necrosis factor alpha in fibroblasts from hip periprosthetic membrane.J Arthroplasty2008;23(4):581–585
28.
QianYZengBFZhangXLJiangYSubstance P augments PGE2 and IL-6 production in titanium particles-stimulated fibroblasts from hip periprosthetic membrane.J Biomed Mater Res A2007;83(2):401–406
29.
ReinholzGGGetzBPedersonLBisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.Cancer Res2000;60(21):6001–6007
30.
KleinBYBen-BassatHBreuerESolomonVGolombGStructurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors.J Cell Biochem1998;68(2):186–194
31.
GiulianiNPedrazzoniMNegriGPasseriGImpicciatoreMGirasoleGBisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo.Bone1998;22(5):455–461
32.
von KnochFJaquieryCKowalskyMEffects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells.Biomaterials2005;26(34):6941–6949
33.
ItonagaISabokbarAMurrayDWAthanasouNAEffect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.Ann Rheum Dis2000;59(1):26–31
34.
GoaterJJO'KeefeRJRosierRNPuzasJESchwarzEMEfficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.J Orthop Res2002;20(2):169–173
MitaniMMiuraYSauraREstrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts.Int J Mol Med2005;15(5):827–832
37.
TiptonDASeshulBADabbousMKEffect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6.J Periodontal Res2011;46(1):39–47
